Milk Thistle - NutraPedia

Back to Table of Contents

Research Overview

Across the studies reviewed here, silymarin (milk thistle extract) has been studied most extensively in the context of chronic liver diseases, with a particular concentration on nonalcoholic fatty liver disease (NAFLD). The dominant outcomes assessed are routine liver biochemistry—especially alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and less consistently gamma‑glutamyl transferase (GGT/γGT). Most evidence comes from systematic reviews and meta-analyses of randomized controlled trials (RCTs), including NAFLD-focused meta-analyses (eight RCTs; hundreds of participants) and broader liver-disease reviews that pool heterogeneous etiologies and interventions (silymarin alone or combined with other nutrients). A smaller subset of reviews also considers metabolic endpoints (e.g., BMI, lipids, insulin resistance) and, more rarely, structural liver outcomes (histology, hepatic fat, liver stiffness).

The strongest and most consistent signal across NAFLD-focused meta-analyses is that silymarin is associated with statistically significant reductions in transaminases (ALT and AST) versus placebo/control. Effect sizes vary by review: one NAFLD meta-analysis reports mean reductions on the order of ~5–9 IU/L for ALT/AST, while a broader liver-disease meta-analysis found statistically significant but very small absolute changes and explicitly judged them to lack clinical relevance; γGT generally shows no clear improvement. Some broader polyphenol and medicinal-plant meta-analyses also conclude that silymarin improves ALT/AST and may improve imaging-based measures (hepatic fat accumulation, liver stiffness), but these conclusions are less uniform and often rely on fewer trials or mixed-quality evidence. Overall, the evidence most strongly supports a modest biochemical improvement (transaminase lowering), while the clinical meaning of this change—particularly in terms of disease modification—remains uncertain.

Key gaps repeatedly highlighted are methodological limitations (risk of bias, low quality, and substantial heterogeneity), variability in formulations/doses and co-interventions, and limited data on clinically meaningful endpoints. Higher-quality, adequately powered RCTs are needed to determine whether enzyme reductions translate into improvements in liver histology (e.g., steatosis, inflammation, fibrosis), validated noninvasive fibrosis measures, and patient-relevant outcomes. Additional research priorities include standardized reporting of silymarin preparations and dosing, longer follow-up to assess durability and fibrosis progression, clearer separation of effects from weight loss and lifestyle change, and more comprehensive safety reporting across diverse patient subgroups and liver disease severities.

1. What conditions has Silymarin been studied for?

  • Nonalcoholic fatty liver disease (NAFLD): Multiple randomized clinical trials and several meta-analyses focused specifically on NAFLD.

  • Mixed “liver diseases” populations: A systematic review/meta-analysis evaluated silymarin across various hepatic diseases and assessed liver enzymes (ALT, AST, γGT).

  • Alcoholic liver disease: A clinical systematic review/meta-analysis reported effects on liver enzymes (e.g., AST) in alcoholic liver disease.

  • Liver cirrhosis (mostly alcoholic; Child-Pugh A noted): A systematic review/meta-analysis reported mortality outcomes in cirrhosis.

  • Chronic hepatitis C virus (HCV) infection: A systematic review/meta-analysis of RCTs assessed oral silymarin and also referenced intravenous silibinin.

  • Amanita phalloides (death cap mushroom) poisoning: A clinical review concluded it is reasonable as supportive therapy (noting this is a specific toxic liver injury context).

2. Does it work in treating those conditions? Summarize the evidence.

  • NAFLD: Evidence suggests silymarin can reduce liver enzymes versus placebo, but study quality concerns and uncertainty about meaningful clinical outcomes remain.

    • One NAFLD meta-analysis (8 RCTs) found a statistically significant greater reduction in transaminases (ALT/AST) vs placebo, “irrespective of weight loss,” but emphasized potential flaws in study quality and that it is unclear whether enzyme reductions translate to histologic improvement.

    • Another NAFLD meta-analysis (8 RCTs; 587 patients) reported mean differences of AST −6.57 U/L and ALT −9.16 U/L vs control, and also found reductions when silymarin was used alone (AST −5.44 U/L; ALT −5.08 U/L).

    • A broader polyphenol meta-analysis (NAFLD) concluded silymarin improved ALT/AST and stated it reduced hepatic fat accumulation and liver stiffness in NAFLD patients (as summarized by that review), but details and certainty depend on the underlying RCTs.

  • Mixed liver diseases (ALT/AST/γGT outcomes): Evidence for enzyme improvement is small and may not be clinically meaningful.

    • A systematic review/meta-analysis (6 trials in meta-analysis) found statistically significant reductions in ALT and AST after silymarin, but explicitly concluded the reductions were minimal and without clinical relevance, with high heterogeneity and low methodological quality. It found no significant change in γGT.

  • Alcoholic liver disease: Limited evidence suggests some enzyme improvement, but not across all markers.

    • A clinical systematic review/meta-analysis reported AST was reduced vs placebo (p = 0.01), while alkaline phosphatase was not.

  • Liver cirrhosis (mostly alcoholic): Evidence is mixed; one analysis suggested reduced liver-related mortality but not total mortality.

    • Total mortality: 16.1% with silymarin vs 20.5% with placebo (not significant).

    • Liver-related mortality: 10.0% with silymarin vs 17.3% with placebo (p = 0.01).

    • The authors concluded it may be reasonable as a supportive element in alcoholic and Child-Pugh A cirrhosis, while also emphasizing the need for a more consistent research program.

  • Chronic HCV infection: Oral silymarin has not shown clear benefit on key intermediate endpoints.

    • Meta-analysis of RCTs found oral silymarin had no significant effect on HCV RNA (P = 0.19) and no significant effect on ALT vs placebo (P = 0.45).

    • Across silymarin (including IV silibinin), HCV RNA “relatively decreased” but was not significant (P = 0.09), and IV administration was noted as needing further study.

  • Amanita phalloides poisoning: The clinical review considered it reasonable as supportive therapy, but the study does not provide pooled effect sizes or trial-level certainty.

3. What health benefits does it have?

  • Reduction in liver enzymes (ALT/AST), especially in NAFLD:

    • NAFLD meta-analyses reported statistically significant reductions in ALT and AST vs control/placebo (e.g., AST −6.57 U/L; ALT −9.16 U/L in one meta-analysis).

    • However, a broader liver-disease meta-analysis found statistically significant but clinically minimal reductions and highlighted heterogeneity/low quality.

  • Possible improvement in NAFLD-related liver characteristics (less certain):

    • A polyphenol meta-analysis summarized that silymarin reduced hepatic fat accumulation and liver stiffness in NAFLD, but this depends on the underlying RCTs and is less consistently established than enzyme changes.

    • One NAFLD meta-analysis explicitly stated more well-designed studies are needed to confirm whether enzyme reductions correspond to histologic improvement.

  • Potential reduction in liver-related mortality in cirrhosis (signal, not definitive):

    • In mostly alcoholic cirrhosis, liver-related mortality was lower with silymarin vs placebo (10.0% vs 17.3%; p = 0.01), while total mortality was not significantly different.

  • Supportive role in specific toxic liver injury (Amanita phalloides poisoning):

    • A clinical review concluded it is reasonable to employ silymarin as a supportive element in therapy, but the study does not quantify benefit.

4. Does it have any downsides or side effects?

  • Tolerability/safety in HCV trials: In a systematic review/meta-analysis of RCTs in chronic HCV infection, silymarin was described as well tolerated.

  • Evidence limitations (a practical downside):

    • Multiple reviews emphasized low methodological quality, high heterogeneity, and/or risk-of-bias concerns, which limits confidence in efficacy estimates.

    • Some statistically significant enzyme reductions were described as not clinically relevant in mixed liver disease populations.

  • Adverse events: The studies reviewed here do not give detailed adverse event rates for silymarin in NAFLD or other liver diseases (beyond “well tolerated” in HCV). Therefore, based on these studies alone, specific side effects and their frequency cannot be reliably summarized.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The studies reviewed here do not report pharmacogenomic analyses (e.g., outcomes stratified by genetic variants affecting drug metabolism/transport, antioxidant pathways, or liver disease risk). Therefore, based on these studies alone, there is no evidence that silymarin is specifically beneficial or harmful for particular genetic variations.

Milk Thistle and Its Benefits in Liver Disease Treatment

Milk Thistle, specifically the extract known as silymarin, has been investigated for its potential in treating liver diseases. It targets oxidative stress and toxicity to protect liver cells from damage.

Eurosil 85® and Silymarin

Eurosil 85® is an enhanced form of silymarin with greater oral bioavailability, often used in clinical research for its efficacy in liver protection.

Antioxidant and Anti-fibrotic Actions

Silymarin functions as an antioxidant and modulates enzymes to reduce cell damage, fibrosis, and cirrhosis. Research has supported its use in conditions like alcoholic and non-alcoholic fatty liver diseases, and cirrhosis, showing a decrease in liver-related deaths and improved metabolic functions in such patients.

Clinical Studies and Safety

Studies reveal silymarin's safety, with minimal adverse effects. It is especially recommended for early intervention in fatty liver disease and acute liver failure to leverage its regenerative capabilities.

Conclusion

In summary, silymarin, derived from milk thistle, shows promising results in protecting the liver and supporting its recovery from various diseases, with an emphasis on early treatment for best outcomes.

References:


  1. Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review
  2. Effect of silymarin on biochemical indicators in patients with liver disease: Systematic review with meta-analysis
    Camila Ribeiro de Avelar, Emile Miranda Pereira, Priscila Ribas de Farias Costa, Rosângela Passos de Jesus, Lucivalda Pereira Magalhães de Oliveira (2017)
  3. Impact of Silymarin in individuals with nonalcoholic fatty liver disease: A systematic review and meta-analysis
    Georgios Kalopitas, Christina Antza, Ioannis Doundoulakis, Antonis Siargkas, Elias Kouroumalis (2021)
  4. The therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease: A meta-analysis (PRISMA) of randomized control trials
    Sheng Zhong, Yuxiang Fan, Qi Yan, Xingyu Fan, Bo Wu (2017)
  5. Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis
    Kailin Yang, Junpeng Chen, Tianqing Zhang, Xiao Yuan, Anqi Ge (2022)
  6. Effect of Medicinal Plants and Natural Products on Liver Enzymes in Non-alcoholic Fatty Liver Patients in Iran: A Systematic Review and Meta-Analysis
    Moloud Fakhri, Hafez Fakheri, Mohammad Azadbakht, Mahmood Moosazadeh, Seyde Sedighe Yousefi (2022)
  7. An updated systematic review with meta-analysis for the clinical evidence of silymarin
    Reinhard Saller, Reto Brignoli, Jörg Melzer, Rémy Meier (2008)
  8. Effects and tolerance of silymarin (milk thistle) in chronic hepatitis C virus infection patients: a meta-analysis of randomized controlled trials
    Zongguo Yang, Liping Zhuang, Yunfei Lu, Qingnian Xu, Xiaorong Chen (2014)


Upload Whole Genome Sequencing (WGS) raw DNA data today and take a deep dive into your genome!

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.

Or if you only have standard microarray data currently, upload raw DNA data to get started with your free DNA raw data analysis today!